CKPT Shareholder Alert: Rosen Law Firm Advises Checkpoint Therapeutics Investors to Seek Legal Counsel Before June 4th Deadline in Securities Class Action
The renowned Rosen Law Firm, a globally recognized investor rights law firm, has issued a crucial reminder to all securities purchasers of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The firm has urged investors who bought Checkpoint Therapeutics securities between March 10, 2021, and December 15, 2023 (Class Period), to act swiftly and secure legal counsel before the lead plaintiff deadline of June 4, 2024. This announcement comes in response to the ongoing securities class action against Checkpoint Therapeutics.
The securities class action lawsuit alleges that Checkpoint Therapeutics and its officers made false and misleading statements to the investing public during the Class Period. According to the lawsuit, Checkpoint Therapeutics failed to disclose adverse information related to the company’s drug development pipeline and its prospects for receiving FDA approval. These alleged failures to disclose pertinent information caused the company’s stock price to trade at artificially inflated levels during the Class Period.
Investors who purchased Checkpoint Therapeutics securities during the Class Period and suffered financial losses are eligible to participate in the securities class action. By doing so, they would be able to seek to recover their losses, potentially representing the class as the lead plaintiff.
The Rosen Law Firm, recognized as one of the top-ranked investor rights law firms worldwide, boasts an impressive track record of recovering substantial compensation for its clients. The firm’s expertise in securities class action litigation positions it as a trusted advisor for individual and institutional investors alike. The attorneys at Rosen Law Firm are committed to protecting the rights of investors and holding corporations accountable for their misleading practices.
With the lead plaintiff deadline set for June 4, 2024, time is of the essence for Checkpoint Therapeutics investors to secure legal counsel. By doing so, investors can rest assured that their interests will be represented by skilled attorneys who will fight to recover their losses resulting from Checkpoint Therapeutics’ alleged misconduct. The lead plaintiff will play a significant role in prosecuting the securities class action and seeking the maximum potential recovery for the class.
Investors who are uncertain about their eligibility to participate in the securities class action or have questions regarding the lead plaintiff process are encouraged to contact the Rosen Law Firm for a free consultation. The firm’s experienced securities attorneys are available to provide guidance and answer any queries investors may have.
In conclusion, Checkpoint Therapeutics investors are strongly advised to act promptly and secure legal counsel before the June 4th lead plaintiff deadline. The securities class action lawsuit presents an opportunity for investors to potentially recover their losses resulting from the alleged misconduct by Checkpoint Therapeutics. The Rosen Law Firm, with its unparalleled expertise and dedication to investor rights, stands ready to advocate for the lead plaintiff and all eligible investors in seeking justice and maximum compensation.
Comments